Klin Farmakol Farm. 2006;20(1):38-40

Is there a connection between statins and cholinergic system?

MUDr. Ľubica Cibičková1, prof. MUDr. Vladimír Palička CSc2
1 II. interní klinika LF UK a Fakultní nemocnice, Hradec Králové
2 Ústav klinické biochemie a diagnostiky FN a LF UK Hradec Králové

Alzheimer´s disease (AD) is a progressive neurodegenerative disease characterized by degeneration and destruction of cholinergic nerve cells. Modern therapy of AD concentrates on influencing the cholinergic system by the inhibition of acetylcholinesterase (AChE). In a recent studies, hypolipidamics such as statins have been shown to have potency to attenuate the risk of AD. However, the exact mechanism of their action on AD has not been clarified yet. Firstly, they may influence of the brain cholinergic system by reducing apolipoprotein E (ApoE) synthesis, since statins inhibit the synthesis of ApoE in brain glia and an inverse correlation between ApoEε4 and cholinacetyltransferase (ChAT) activity was found. Administration of statins may augment ChAT activity by the inhibition of ApoE synthesis thereby increasing the amount of desirable acetylcholine (ACh) in synapses. Secondly, statins also lower the synthesis of cholesterol, a substance higher levels of which support the formation of amyloid beta (Aβ). Because Aβ reduces the degradation of acetylcholinesterase (AChE), statins might prevent this unfavourable build-up of AChE by suppressing the formation of Aβ. Moreover, levels of Aβ correlate with ChAT activity, that is why statins might, in addition, enhance desirable activity of ChAT, and hence, by this dual mechanism, contribute to the elevation of the amount of ACh available in synapses. In one paper, direct influence of some statins on cholinesterases has already been described.

In spite of the above-mentioned hypotheses about the potential influence of statins on cholinergic system in patients with AD, it cannot be excluded that statins affect AD in other ways such by their antiinflammatory effect and by up-regulation of nitric oxide synthesis. Futher studies are needed to elucidate the function of statins in the prevention and/or treatment of AD. In concert with that, the number of published papers on this theme shows an enormous interest of researchers in this drug group.

Keywords: Alzheimer´s disease, statins, cholinergic system

Published: March 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Cibičková Ľ, Palička V. Is there a connection between statins and cholinergic system? Klin Farmakol Farm. 2006;20(1):38-40.
Download citation

References

  1. Arvanitakis Z, Lucas JA, Graff-Radford NR. Correlation between serum cholesterol parameters and plasma amyloid beta protein. Neurobiol Aging 2000; 21: 96. Go to original source...
  2. Bales KR, et al. Apolipoprotein E is essential for amyloid deposition in the APP (V717F) transgenic mouse model of Alzheimer´s disease. Proc Natl Acad Sci USA 1999; 96: 15233-15238. Go to original source... Go to PubMed...
  3. Bales KR, et al. Diet-induced hyperlipidemia accelerates amyloid deposition in the APPv717f transgenic mouse model of Alzheimer´s disease. Neurobiol Aging 2000; 21: 254. Go to original source...
  4. Beffert U, Poirier J. Apolipoprotein E, plaques, tangles and cholinergic dysfunction in Alzheimer´s disease. Ann. N.Y. Acad. Sci. 1996; 777: 166-174. Go to original source... Go to PubMed...
  5. Buxbaum JD, Geoghagen NS, Friedhoff LT. Cholesterol Depletion with physiological concentrations of a statin decreases the formation of the Alzheimer amyloid A? peptide. J Alzheimers Dis. 2001 Apr; 3 (2): 221-229. Go to original source... Go to PubMed...
  6. Cole SL, Grudzien A, Manhart I, et al. A tale of two statins: The effect of lovastatin and simvastatin on APP metabolism (abstract). Neurobiol Aging 2004; 25 (Suppl 2): S77. Go to original source...
  7. Costa DA, et al. Apolipoprotein is required for the formation of filamentous amyloid, but not for amorphous Abeta deposition, in an AbetaPP/PS double transgenic mouse model of Alzheimer´s disease. J Alzheimers Dis 2004 Oct; 6 (5): 509-514. Go to original source... Go to PubMed...
  8. Crisby M, Carlson LA, Winblad B. Statins in the prevention and treatment of Alzheimer disease. Alzheimer Dis Assoc Disord. 2002 Jun-Sep; 16 (3): 131-136. Go to original source... Go to PubMed...
  9. Darvesh S, Martin E, Walsh R, Rockwood K. Differential effects of lipid-lowering agents on human cholinesterases. Clinical Biochemistry 2004; 37: 42-49. Go to original source... Go to PubMed...
  10. Eckert GP, et al. Cholesterol modulates amyloid beta-peptide´s membrane interactions. Pharmacopsychiatry. 2003 Sep; 36 (Suppl 2): 136-143. Go to original source... Go to PubMed...
  11. Fars ER, et al. The role of cholesterol in the biosynthesis of beta-amyloid. Neuroreport 1999; 10: 1699-1705. Go to original source... Go to PubMed...
  12. Fassenbender K, et al. Simvastatin strongly reduces levels of Alzheimer´s disease ?-amyloid peptides A ?42 and A ?40 in vitro and in vivo. 2001 May 8; 98 (10): 5856-5861. Go to original source... Go to PubMed...
  13. Hőschl C, et al. Alzheimerova choroba. Galén, 1999: 13-23.
  14. Hu W, Gray NW, Brimijoin S. Amyloid-beta increases acetylcholinesterase expression in neuroblastoma cells by reducing enzyme degradation. J Neurochem 2003 Jul; 86 (2): 470-478. Go to original source... Go to PubMed...
  15. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet 2001 Feb 17; 357 (9255): 562. Go to original source...
  16. Jirák R. Farmakoterapie Alzheimerovy choroby. Klin Farmakol Farm 2004; 18: 212-214.
  17. Kim KW, Suh YJ, Park WY, et al. Chopine acetyltransferase G+4 A polymorphism confers a risk for LAzheimer´s disease in concert with Apolipoprotein E ?4. Neuroscience Letters 2004; 366: 182-186. Go to original source... Go to PubMed...
  18. Kuo YM, et al. Elevated low-density lipoproteid in Alzheimer´s disease correlates with brain A-beta 1-42 levels. BBRC 1998; 252: 711-715. Go to original source... Go to PubMed...
  19. Lahiri DL. Apolipoprotein E as a target for developing new therapeutics for Alzheimer´s disease based on studies from protein, RNA, and regulatory region of the gene. J Mol Neurosci. 2004; 23 (3): 225-233. Go to original source... Go to PubMed...
  20. Masliah E, Alford M, Adame A, et al. Abeta1-42 promotes cholinergic sprouting in patients with AD and Lewy body variant of AD. Neurology 2003 Jul 22; 61 (2): 206-211. Go to original source... Go to PubMed...
  21. Michikawa M. Cholesterol paradox: is high total or low HDL cholesterol level a risk for Alzheimer´s disease? J Neurosci Res. 2003 Apr 15; 72 (2): 141-146. Go to original source... Go to PubMed...
  22. Naidu A, et al. Secretion of apolipoprotein E by brain glia requires protein prenylation and is supressed by statins. Brain Res. 2002 Dec 20; 958 (1): 100-111. Go to original source... Go to PubMed...
  23. Patočka J, Strunecká A, Řípová D. Cholinesterases and their significance for etiology, diagnostics and therapy of Alzheimer´s diasease. Čs Fyziol 2001; 50 (1), 4-10.
  24. Puglielli L, Konopka G, Pack-Chung E, et al. Acyl-coenzyme A:cholesterol acyltransferaze modulates the generation of the amyloid ?-peptide. Nature Cell Biology 2001 Oct; 3: 905-912. Go to original source... Go to PubMed...
  25. Rockwood K, et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol. 2002 Feb; 59 (2): 223-227. Go to original source... Go to PubMed...
  26. Simons, et al. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci (USA) 1998; 95: 6460-6464. Go to original source... Go to PubMed...
  27. Sparks DL. Intraneuronal ?-amyloid immunoreactivity in the CNS. Neurobiol Aging 1996; 17: 291-299. Go to original source... Go to PubMed...
  28. Sparks DL, et al. HMG-CoA reduktase inhibitors (statins) in the treatment of Alzheimer´s disease and why it would be ill-advise to use one that crosses the blood-brain barrier. J Nutr Health Aging. 2002; 6 (5): 324-331.
  29. Stuve O, et al. Statins as potential therapeutic agents in neuroinflammatory disorders. Curr Opin Neurol. 2003 Jun; 13 (3): 393-401. Go to original source...
  30. Wolozin B, Kellman W, Ruocceau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arch Neurol. 2000 Oct; 57 (10): 1439-1443. Go to original source... Go to PubMed...
  31. Zamrini E, McGwin G, Roseman JM. Association between statin use and Alzheimer´s disease. Neuroepidemiology. 2004 Jan-Apr; 23 (1-2): 94-98. Go to original source... Go to PubMed...




Clinical Pharmacology and Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.